ResearcherUniversitätsmedizin GöttingenActive in the last 2 years

Matthias Dobbelstein

ORCID-verified (high confidence, 0.95), identity_conf@1As of 7 November 2026

Matched on ORCID iD 0000-0001-5052-3967; OpenAlex author ID A5004540529. Sources: OpenAlex.

Their work

Papers: 4 (first author 0, last author 3)
Trials: 0
Grants: 0
Labs led: 1
Collaborators: 17

Papers, trials and grants by year

2014: 1 paper · 2015: none · 2016: none · 2017: none · 2018: none · 2019: none · 2020: none · 2021: 1 paper · 2022: none · 2023: none · 2024: none · 2025: 1 paper · 2026: 1 paper

Papers 4

Closest collaborators

The 17 strongest of 17 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

Adi Danieli‐Mackay · 2 shared papers, 2025–2026 · strength 0.43
- Paper Targeting addiction to HMGB2-driven transcriptional programs in pancreatic cancer. DOI 10.1016/j.celrep.2026.117649 ↗
- Paper Simultaneous targeting of KRAS and CDK4 synergistically induces durable growth arrest in pancreatic cancer cells. DOI 10.1038/s41419-025-08362-w ↗
Gabriela Salinas · 2 shared papers, 2025–2026 · strength 0.43
- Paper Targeting addiction to HMGB2-driven transcriptional programs in pancreatic cancer. DOI 10.1016/j.celrep.2026.117649 ↗
- Paper Simultaneous targeting of KRAS and CDK4 synergistically induces durable growth arrest in pancreatic cancer cells. DOI 10.1038/s41419-025-08362-w ↗
Elisabeth Heßmann · 2 shared papers, 2021–2025 · strength 0.35
- Paper Simultaneous targeting of KRAS and CDK4 synergistically induces durable growth arrest in pancreatic cancer cells. DOI 10.1038/s41419-025-08362-w ↗
- Paper HSP90 Inhibition Synergizes with Cisplatin to Eliminate Basal-like Pancreatic Ductal Adenocarcinoma Cells. DOI 10.3390/cancers13246163 ↗
Argyris Papantonis · 1 shared paper, 2026 · strength 0.22
- Paper Targeting addiction to HMGB2-driven transcriptional programs in pancreatic cancer. DOI 10.1016/j.celrep.2026.117649 ↗
Tiago De Oliveira · 1 shared paper, 2026 · strength 0.22
- Paper Targeting addiction to HMGB2-driven transcriptional programs in pancreatic cancer. DOI 10.1016/j.celrep.2026.117649 ↗
Emre Taylan Duman · 1 shared paper, 2026 · strength 0.22
- Paper Targeting addiction to HMGB2-driven transcriptional programs in pancreatic cancer. DOI 10.1016/j.celrep.2026.117649 ↗
Shiv K. Singh · 1 shared paper, 2026 · strength 0.22
- Paper Targeting addiction to HMGB2-driven transcriptional programs in pancreatic cancer. DOI 10.1016/j.celrep.2026.117649 ↗
Lena‐Christin Conradi · 1 shared paper, 2026 · strength 0.22
- Paper Targeting addiction to HMGB2-driven transcriptional programs in pancreatic cancer. DOI 10.1016/j.celrep.2026.117649 ↗
Lukas Klein · 1 shared paper, 2026 · strength 0.22
- Paper Targeting addiction to HMGB2-driven transcriptional programs in pancreatic cancer. DOI 10.1016/j.celrep.2026.117649 ↗
Constanza Tapia Contreras · 1 shared paper, 2025 · strength 0.21
- Paper Simultaneous targeting of KRAS and CDK4 synergistically induces durable growth arrest in pancreatic cancer cells. DOI 10.1038/s41419-025-08362-w ↗
Carolin Schneider · 1 shared paper, 2025 · strength 0.21
- Paper Simultaneous targeting of KRAS and CDK4 synergistically induces durable growth arrest in pancreatic cancer cells. DOI 10.1038/s41419-025-08362-w ↗
Maj-Britt Paulsohn · 1 shared paper, 2025 · strength 0.21
- Paper Simultaneous targeting of KRAS and CDK4 synergistically induces durable growth arrest in pancreatic cancer cells. DOI 10.1038/s41419-025-08362-w ↗
Günter Schneider · 1 shared paper, 2025 · strength 0.21
- Paper Simultaneous targeting of KRAS and CDK4 synergistically induces durable growth arrest in pancreatic cancer cells. DOI 10.1038/s41419-025-08362-w ↗
Katharina M. Ewers · 1 shared paper, 2021 · strength 0.13
- Paper HSP90 Inhibition Synergizes with Cisplatin to Eliminate Basal-like Pancreatic Ductal Adenocarcinoma Cells. DOI 10.3390/cancers13246163 ↗
Xin Wang · 1 shared paper, 2021 · strength 0.13
- Paper HSP90 Inhibition Synergizes with Cisplatin to Eliminate Basal-like Pancreatic Ductal Adenocarcinoma Cells. DOI 10.3390/cancers13246163 ↗
Shilpa Patil · 1 shared paper, 2021 · strength 0.13
- Paper HSP90 Inhibition Synergizes with Cisplatin to Eliminate Basal-like Pancreatic Ductal Adenocarcinoma Cells. DOI 10.3390/cancers13246163 ↗
Frederik Köpper · 1 shared paper, 2014 · strength 0.06
- Paper The MAPK-activated protein kinase 2 mediates gemcitabine sensitivity in pancreatic cancer cells. DOI 10.4161/cc.28292 ↗

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.